Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Voyageur Pharmaceuticals ( (TSE:VM) ).
Voyageur Pharmaceuticals has signed a collaboration and funding agreement with Bayer that could provide up to USD 2.35 million in milestone-based funding to advance a potential iodine production project in Oklahoma for use in contrast media drugs. Under the deal, Bayer receives exclusive rights to negotiate an offtake agreement for iodine from the project, while all project-related intellectual property remains with Voyageur.
The parties will first complete a feasibility study on the iodine extraction plant, funded in stages by Bayer, and may later consider an offtake-linked production financing arrangement in which Bayer would provide capital and Voyageur would operate the project. In parallel, Voyageur is progressing its own feasibility work on a broader radiology drug production project for barium and iodine contrast agents, a dual track that could secure non-dilutive financing for a new manufacturing facility and strengthen North American healthcare supply chain resilience in a fast-growing global contrast media market.
The most recent analyst rating on (TSE:VM) stock is a Sell with a C$0.16 price target. To see the full list of analyst forecasts on Voyageur Pharmaceuticals stock, see the TSE:VM Stock Forecast page.
Spark’s Take on TSE:VM Stock
According to Spark, TipRanks’ AI Analyst, TSE:VM is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, large losses, and rising cash burn that implies funding/dilution risk), only partly offset by low leverage and positive equity. Technical indicators are broadly neutral and provide limited support, while valuation is constrained by negative earnings and no dividend yield.
To see Spark’s full report on TSE:VM stock, click here.
More about Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. is a Canadian developer of pharmaceutical-grade barium and iodine used in medical imaging contrast media drugs, with projects anchored by its Frances Creek barium resource in British Columbia and planned iodine production from the Anadarko Basin in the U.S. The company is positioning itself as a key participant in the global supply chain for contrast media, with a strategic focus on becoming the first domestic producer of both iodine and barium contrast agents in the United States.
YTD Price Performance: -17.65%
Average Trading Volume: 105,410
Technical Sentiment Signal: Buy
Current Market Cap: C$25.9M
See more insights into VM stock on TipRanks’ Stock Analysis page.